

## Special Issue

# Advances in Cancer Vaccines: From Bench to Bedside

### Message from the Guest Editors

This Special Issue will cover the latest progress in cancer vaccine research and developments. We aim to provide a comprehensive overview of recent developments in cancer vaccines, including novel targets, formulations, and delivery systems. Furthermore, we intend to explore the potential of combination therapies that incorporate cancer vaccines and the identification of biomarkers to guide patient selection and monitoring. Additionally, the Special Issue will cover the research on mRNA-based cancer vaccines, which represent a promising new approach to cancer immunotherapy due to their flexibility and speed of development. This Special Issue will be of immense interest to researchers, clinicians, and policymakers involved in cancer immunotherapy, and it is hoped that it will make a significant contribution to the field of cancer therapy, and have a positive impact on patient outcomes. We invite submissions of original research articles, reviews, and perspectives that provide insights into cancer vaccine development, immune correlates of protection, regulatory and ethical considerations, and other relevant topics. We look forward to your contributions and collaboration.

---

### Guest Editors

Prof. Dr. Qizhi Cathy Yao

Dr. Alok K. Mishra

Dr. Sunil K. Malonia

---

### Deadline for manuscript submissions

closed (31 July 2024)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/172029](https://mdpi.com/si/172029)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).